George R. Thompson III, MD

University of California, Davis Medical Center

Disclosure(s): Astellas: Advisor/Consultant, Grant/Research Support; Basilea: Advisor/Consultant, Grant/Research Support; Cidara: Advisor/Consultant, Grant/Research Support; F2G: Advisor/Consultant, Grant/Research Support; GSK: Advisor/Consultant, Grant/Research Support; Melinta: Advisor/Consultant, Grant/Research Support; Mundipharma: Advisor/Consultant, Grant/Research Support; Scynexis: Advisor/Consultant, Grant/Research Support

Poster(s):

• (P-147) Clinical Outcomes of Typhlitis: A Large Single Center Case Series
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-1187) Olorofim for the treatment of Central Nervous System (CNS) invasive fungal infections (IFI) in patients with limited or no treatment options: a sub-analysis of an open-label, single-arm, Phase 2b trial (Study 32; NCT03583164)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1954) Clinical, Laboratory, and Biomarker Predictors of 90-Day Mortality in Non-HIV, Non-Transplant Pneumocystis Pneumonia
  Wednesday, October 22, 2025

  12:15 PM - 1:30 PM US ET